Navigation Links
SeraCare Shareholders Approve Acquisition by Linden Capital Partners
Date:4/18/2012

MILFORD, Mass., April 18, 2012 /PRNewswire/ -- SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, announced that, at a special meeting of shareholders held today, its shareholders voted to adopt the merger agreement with Project Plasma Holdings Corporation and Project Plasma Merger Corp., affiliates of Linden Capital Partners. Linden Capital Partners is a Chicago-based private equity firm that focuses on middle market leveraged buyout investments in the healthcare and life science industries.

(Logo:  http://photos.prnewswire.com/prnh/20110324/NE70714LOGO )

Under the terms of the merger agreement, holders of outstanding shares of common stock of SeraCare will receive $4.00 per share. The transaction is expected to close on Friday, April 20, 2012 after the close of business, subject to the satisfaction of customary closing conditions. In addition, shareholders also voted to approve certain compensation arrangements for SeraCare's named executive officers in connection with the merger.

About Linden Capital Partners:

Linden is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's investment strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden has advised SeraCare that it currently manages $575 million in capital. For additional information, please visit www.lindenllc.com.

About SeraCare Life Sciences, Inc.:

SeraCare serves the g
'/>"/>

SOURCE SeraCare Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SeraCare Life Sciences Secures $20 Million Credit Facilities
2. SeraCare Life Sciences to Report First Quarter 2011 Financial Results on February 11, 2011
3. SeraCare Reports First Quarter Fiscal Year 2011 Results
4. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
5. SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors
6. SeraCare Reports Second Quarter Fiscal Year 2011 Financial Results
7. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
8. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
9. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
10. Mymetics Corporation Important Shareholders Information Conference Call
11. Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Boston’s Adult Stem Cell Technology Center, LLC ... stem cell biotechnologies. Currently the company holds seven ... patent applications currently under examination by the U.S. Patent ... of the most vexing problems in adult stem cell ... are difficult to identify; and they have been difficult ...
(Date:7/30/2014)... , July 30, 2014 Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... results and highlights for the quarter ended June 30, ... financial markets close. Regulus will host ... 2014, at 5:00 pm Eastern Daylight Time to discuss ...
(Date:7/30/2014)... W. R. Grace & Co. (NYSE: ... REVELERIS® Prep purification system , a dual-mode instrument ... researchers to perform both flash and preparative liquid ... the REVELERIS® Prep purification system, researchers can easily ... a simple touch of the screen, giving them ...
(Date:7/30/2014)... July 30, 2014 A study presented ... safety and efficacy of CSL Behring,s C1 Inhibitor ... transplants in highly sensitized patients. C1-INH is a ... complement system. The study shows that ... in the levels of complement components 3 and ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Grace Launches New REVELERIS® Prep Purification System 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... 0 clinical testing has been gaining acceptance and ... development process in the years to come. The ... and technology dependence is also expected to result ... in this sector.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )"There is every ...
... Health Care Business Conference, an MBA-student organized event, will be held ... distinguished speakers and panelists from Healthcare Services, Investment, Pharma, Biotech, and ... ... 10, 2009 -- The 2009 Wharton Health Care Business Conference ...
... Feb. 10 DSM Biologics and Crucell N.V. (Euronext, ... today that they have entered into an agreement with ... Vendor Network. Under the terms of the agreement, Bioceros ... licensees of the PER.C6(R) cell line located in the ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 314th Annual Wharton Health Care Business Conference to Feature CEOs from WebMD, McKesson, Humana and Given Imaging 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 2DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 3DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 4DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins 5
(Date:7/31/2014)... LA Dr. Oren Tessler, Assistant Professor of Clinical ... of Medicine, is part of a team of plastic ... using a method to screen and select patients for ... of the patients who underwent this surgery to decompress ... got a bonus cosmetic eyelid surgery. The study, which ...
(Date:7/31/2014)... NXT-ID, Inc., (NXTD: OTCQB) a biometric authentication company ... and consumers wanting to learn more about its  ... on-air today, July 31 st . ... featured in a segment of NewsWatch, a weekly ... the History Channel, FYI Network today. ...
(Date:7/30/2014)... by the Red Queen in Lewis Carroll,s Through ... Illinois and National University of Singapore improved a ... evolve over decades to millions of years. , ... for competition, incorporates the "Red Queen Effect," an ... the 1970s, which suggests that organisms must constantly ...
Breaking Biology News(10 mins):Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 3Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... choices for our nation,s schoolchildren is a hot-button issue ... team of researchers from Cornell University have recently identified ... vegetables and salad items. Laura Smith, a researcher ... findings of the study "Convenience Drives Choice in School ...
... Inc. (Nasdaq: OKSB ), ("Southwest"), today announced that it has priced its ... the public of $12.50 per share for net proceeds of approximately ... size of approximately $40 million .  The offering is expected to close ... , , ...
... PHILADELPHIA , April 27 Mondre Energy, Inc. (MEI), a ... Exeter Associates to address a wide range of energy issues on behalf ... Power Plant Research Program works to ensure that Maryland meets ... , , ...
Cached Biology News:Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 2Southwest Bancorp, Inc. Announces Pricing of $50 Million Underwritten Public Offering of Common Shares 3Mondre Energy Partnering with Exeter Associates to Address Energy Issues in Maryland 2
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
... pACHLT-A-BFP Baculovirus Transfer Vector is a derivative of ... gene for blue fluorescent protein (BFP), followed by ... (MCS).,Foreign genes are expressed as BFP-6xHis fusion proteins ... enzyme,sites (EcoR I, Stu I, Sac I, Not ...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Biology Products: